Tesamorelin and ipamorelin end in the same letters, turn up in the same threads, and get sold as a pair, which is why people assume they are two versions of one thing. They aren’t. Tesamorelin imitates the hormone the hypothalamus sends to the pituitary. Ipamorelin imitates a gut hormone’s signal at a different receptor on the same gland. The two molecules start at different doors and arrive at the same room, and almost everything else about them differs, including how much human research exists. This tesamorelin vs ipamorelin comparison covers the receptors, the evidence on each side, what the pairing rests on, and what a lab report should show. Everything below describes laboratory research.
TesamorelinTesamorelin vs ipamorelin: what is the difference?
Tesamorelin is a stabilized growth hormone-releasing hormone analog, GHRH(1-44), acting on the GHRH receptor. Ipamorelin is a five amino acid ghrelin-receptor agonist, acting on a GHRP-like receptor. Both lead to growth hormone release, but through separate pathways. The other difference is the record: tesamorelin has pooled phase 3 trials with a CT-scan endpoint, and ipamorelin has a selectivity paper, a rat model and a phase 2 trial in another field. Which is “better” depends on the question, and the evidence doesn’t rank them.
Tesamorelin vs ipamorelin side by side
Tesamorelin’s size, price and batch data are pulled live from the product and certificate pages. The ipamorelin column says what to ask a seller. Searched as ipamorelin vs tesamorelin, the table is the same.
| Tesamorelin | Ipamorelin | |
|---|---|---|
| What it is | A stabilized GHRH analog, GHRH(1-44) | A pentapeptide ghrelin-receptor agonist |
| Receptor | GHRH receptor | GHRP-like (ghrelin) receptor |
| Best-known research finding | Visceral fat reduced against placebo by CT in pooled phase 3 trials | Growth hormone release without a rise in ACTH or cortisol in swine |
| Largest human trial | 806 patients across two pooled phase 3 studies | 117 patients in a phase 2 postoperative ileus trial |
| Size and price | 10mg vial, $89.99 | Varies by seller |
| Latest batch purity (HPLC) | 99.5% | Ask the seller for the batch report |
| Certificate | Tesamorelin COA | Ask the seller for the certificate |
The suffix trap: why tesamorelin and ipamorelin look related
Tesamorelin, sermorelin and ipamorelin all end in “-relin,” a convention that implies a family, and it half works. Tesamorelin and sermorelin are GHRH analogs on the same receptor. Ipamorelin belongs to the ghrelin-receptor family, the one that includes GHRP-6 and GHRP-2. The shared ending describes a shared outcome, growth hormone release, and hides a different route. A paper on one tells you nothing about the other’s receptor biology. The growth hormone peptides guide maps the whole family.
What the tesamorelin research covers
Falutz and colleagues pooled two phase 3 studies of 806 HIV patients on antiretroviral therapy with excess abdominal fat. At 26 weeks, CT-measured visceral fat fell against placebo, with a treatment effect of 15.4 percent, and subcutaneous fat didn’t change meaningfully. Dhillon’s review in Drugs adds that visceral fat re-accumulated when treatment stopped. Stanley and colleagues found a greater drop in liver fat than placebo in 61 people with HIV and fatty liver disease. These are trials in a single population with imaging endpoints, and the tesamorelin peptide page covers the compound in full.
What the ipamorelin research covers
Ipamorelin’s best-known paper is Raun and colleagues in the European Journal of Endocrinology. They described it as the first selective growth hormone secretagogue: in swine, GHRP-6 and GHRP-2 raised ACTH and cortisol, but ipamorelin did not, even at doses more than 200-fold above the level that released growth hormone. The later work concerns the gut. A rat model of postoperative ileus found repeated dosing increased fecal output, food intake and weight gain, and the phase 2 trial in bowel surgery patients found it well tolerated and no significant efficacy difference from placebo, with a median time to a tolerated meal of 25.3 hours against 32.6 for placebo (p = 0.15).
Tesamorelin and ipamorelin together: what the blend rests on
The case for pairing a GHRH analog with a ghrelin-type compound comes from a 1995 study in the Journal of Clinical Endocrinology and Metabolism, where healthy controls given GHRH plus GHRP-6 released more growth hormone than the sum of the two given separately. That synergy is the whole logic, and it rests on GHRP-6 and native GHRH, not on tesamorelin and ipamorelin. The tesamorelin and ipamorelin blend post explains the combination and its limits. A pre-mixed vial also fixes the ratio, so a study that wants one compound alone can’t separate them afterward.
Which research question fits tesamorelin and which fits ipamorelin
A question about visceral fat, liver fat or body composition in a defined clinical population maps onto tesamorelin, because that’s what its trials measured. A question about whether a secretagogue can raise growth hormone without a cortisol or ACTH rise maps onto ipamorelin, because that’s what Raun’s paper tested. A question about gut motility after surgery maps onto ipamorelin’s ileus work, which has nothing to do with growth hormone targets. A design that asks whether two signals produce more than one would need the pair as separate arms plus a combined arm, and no paper cited here has built that experiment with these two compounds.
Searches for muscle growth: what the papers measured
Many people search tesamorelin vs ipamorelin for muscle growth, and it’s worth being exact about the evidence. The tesamorelin trials measured visceral fat, trunk fat, waist circumference and lipids. The ipamorelin trial measured time to a tolerated meal. The swine paper measured hormone release. None of the papers cited here has muscle growth as an endpoint. Raising growth hormone and growing muscle are different claims, and the gap between them is where marketing language tends to live.
How to read a tesamorelin and ipamorelin stack claim
Pages about the pair usually describe tesamorelin as the one that “targets abdominal fat” and ipamorelin as the one that “supports overall growth hormone,” then call the combination powerful. Each half borrows from a different paper. The abdominal fat language comes from the HIV lipodystrophy trials, which enrolled a specific patient population. The growth hormone language comes from animal work. The word powerful comes from nowhere. A useful habit is to ask three things of any sentence: which paper, which compound, and which endpoint. If the answer to the second is “the pair,” the claim has outrun the evidence, since the pair hasn’t been the subject of those trials.
Tesamorelin vs ipamorelin in women’s research
The abstracts cited here don’t report results by sex, and growth hormone secretion differs by sex and across the menstrual cycle. A woman framing her own research question will want sex-stratified data for both compounds, and it is thin. The tesamorelin for women page covers the compound with the deeper record.
What the tesamorelin and ipamorelin studies can’t tell you
The tesamorelin trials enrolled people with HIV and don’t transfer to other populations or to a laboratory model. Ipamorelin’s human trial asked about gut function, so its growth hormone record is mainly animal and in vitro. Nobody has published a head-to-head of the two in the papers cited here, and growth hormone release is a hormone measurement, not a body-composition outcome. Pages that rank the two are combining separate papers with different species and endpoints.
Tesamorelin COA: what a lab report shows, and what to ask for on ipamorelin
Every Healio Peptides batch is tested by an independent US laboratory before release, and the report is published before you order. This is the current tesamorelin batch.
| Tesamorelin | |
|---|---|
| Batch | HEALIO-TESA-2616 |
| Purity (HPLC) | 99.5% |
| Identity (ESI-MS) | Confirmed, conforms to the reference standard (5135.86) |
| Endotoxins (LAL) | Under 0.5 EU/mg (limit 5 EU/mg) |
Ask for the same four lines from any seller of ipamorelin: purity by HPLC, identity by mass spectrometry, an endotoxin result, and a lot number that matches the vial. Ipamorelin is a pentapeptide, so a wrong residue is hard to spot by eye and the identity line carries the weight. Tesamorelin is a 44 amino acid peptide with more room for synthesis errors, which makes its identity line worth a close read too. Reading a peptide certificate of analysis explains each row.
Tesamorelin price and format
Healio Peptides lists tesamorelin as a 10mg vial, lyophilized powder, at $89.99, which is $9.00 per mg. Ipamorelin strengths and prices vary by seller, so compare cost per milligram. Reconstitution uses bacteriostatic water for sale, and the tesamorelin calculator turns vial strength and water volume into a concentration. How to reconstitute peptides covers the handling.
Where to buy tesamorelin for research
Whichever supplier you use, look for a published certificate before anything else. Every Healio Peptides batch ships with a third-party report, and orders go out from the United States. The tesamorelin for sale page carries the certificate before you order, and the peptides for weight loss category shows the neighboring compounds.
Tesamorelin vs ipamorelin: frequently asked questions
What is the difference between tesamorelin and ipamorelin?
Tesamorelin is a GHRH analog acting on the GHRH receptor. Ipamorelin is a ghrelin-receptor agonist. Both lead to growth hormone release, by separate pathways.
Is ipamorelin or tesamorelin better?
The evidence doesn’t rank them. Tesamorelin has pooled phase 3 trials with a CT-scan endpoint in one population, and ipamorelin has a selectivity paper, an animal model and a gut trial. They answer different questions.
Why are tesamorelin and ipamorelin combined?
They act on separate receptors. The rationale comes from older work showing GHRH plus GHRP-6 released more growth hormone than the sum of each, though the two compounds haven’t been tested head to head in the papers cited here.
Is ipamorelin selective for growth hormone?
In swine, Raun and colleagues found it released growth hormone without raising ACTH or cortisol, unlike GHRP-6 and GHRP-2. That is a result from one animal study.
Are tesamorelin and ipamorelin FDA approved?
Nothing on this page is a statement about any product’s legal status or medical advice. A 2011 review describes a pharmaceutical tesamorelin as indicated for abdominal fat in HIV-associated lipodystrophy, which says nothing about research-grade vials. Healio Peptides sells tesamorelin strictly for laboratory research.
Do tesamorelin and ipamorelin reviews tell me anything useful?
Reviews mix different products, forms and expectations, so they say little about any one vial. A batch certificate says more: it ties a purity and identity result to a lot number you can check.
More on tesamorelin and growth hormone peptides
- CJC-1295 and ipamorelin vs tesamorelin, the pairing against the single analog.
- Sermorelin vs tesamorelin, the two GHRH analogs compared.
- CJC-1295 and ipamorelin vs sermorelin, one signal against two.
Healio Peptides supplies research compounds for laboratory use only. They are not for human or veterinary use, have not been evaluated by the FDA, and nothing on this page is medical advice.